BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 18264914)

  • 1. [Nephrogenic systemic fibrosis].
    Cavallini L; Abaterusso C; Bedogna V; Pertica N; Loschiavo C; Lupo A
    G Ital Nefrol; 2008; 25(1):14-20. PubMed ID: 18264914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.
    Kallen AJ; Jhung MA; Cheng S; Hess T; Turabelidze G; Abramova L; Arduino M; Guarner J; Pollack B; Saab G; Patel PR
    Am J Kidney Dis; 2008 Jun; 51(6):966-75. PubMed ID: 18501784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gadolinium: a true problem for the nephrologists?].
    Balducci A; Tamburrini O
    G Ital Nefrol; 2008; 25(1):3-4. PubMed ID: 18264906
    [No Abstract]   [Full Text] [Related]  

  • 4. MRI gadolinium-based contrast agents. Radiologists beware!
    Goullé JP; Cattanéo A; Saussereau E; Mahieu L; Guerbet M; Lacroix C
    Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P
    J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extracellular Gd-CA: differences in prevalence of NSF.
    Thomsen HS; Marckmann P
    Eur J Radiol; 2008 May; 66(2):180-3. PubMed ID: 18342468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Nephrogenic systemic fibrosis].
    Breitschaft A; Stahlmann R
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?
    Panesar M; Boateng F; Patel SS; Masood SF; Mahajan P; Patel N; Murray B
    Hemodial Int; 2010 Jul; 14(3):289-94. PubMed ID: 20662951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
    Andréjak M; Thuillier D; Lok C; Gras-Champel V
    Therapie; 2007; 62(2):169-72. PubMed ID: 17582319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue gadolinium deposition and fibrosis mimicking nephrogenic systemic fibrosis (NSF)-subclinical nephrogenic systemic fibrosis?
    Boyd AS; Sanyal S; Abraham JL
    J Am Acad Dermatol; 2010 Feb; 62(2):337-42. PubMed ID: 19939504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
    Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
    AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Nephrogenic systemic fibrosis after application of gadolinium-based contrast agents--a status paper].
    Heinrich M; Uder M
    Rofo; 2007 Jun; 179(6):613-7. PubMed ID: 17497597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.
    Rydahl C; Thomsen HS; Marckmann P
    Invest Radiol; 2008 Feb; 43(2):141-4. PubMed ID: 18197066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrogenic systemic fibrosis: epidemiology update.
    Marckmann P
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):315-9. PubMed ID: 18408485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrogenic systemic fibrosis--implications for nephrologists.
    Saab G; Abu-Alfa A
    Eur J Radiol; 2008 May; 66(2):208-12. PubMed ID: 18342470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis (NSF)?
    Thomsen HS; Morcos SK; Dawson P
    Clin Radiol; 2006 Nov; 61(11):905-6. PubMed ID: 17018301
    [No Abstract]   [Full Text] [Related]  

  • 17. The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report.
    Wiedemeyer K; Kutzner H; Abraham JL; Thakral C; Carlson JA; Tran TA; Hausser I; Hartschuh W
    Am J Dermatopathol; 2009 Oct; 31(7):674-81. PubMed ID: 19633532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nephrogenic systemic fibrosis: history and epidemiology.
    Thomsen HS
    Radiol Clin North Am; 2009 Sep; 47(5):827-31, vi. PubMed ID: 19744597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nephrogenic systemic fibrosis and use of MR contrast media].
    Christiansen RE; Sviland L; Sekse I; Svarstad E
    Tidsskr Nor Laegeforen; 2009 Jan; 129(3):180-2. PubMed ID: 19180161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of NSF on the care of patients with kidney disease.
    Abu-Alfa A
    J Am Coll Radiol; 2008 Jan; 5(1):45-52. PubMed ID: 18180009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.